C. Rooney

H. Heslop, C. Rooney, C. Bollard, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Suicide genes as safety switches in T lymphocytes.

C. Rooney, K. Straathof, D. Spencer, 2003, Cytotherapy.

Modeling cytokine release syndrome

C. Rooney, T. Sauer, 2018, Nature Medicine.

Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).

H. Heslop, C. Rooney, P. Reinke, 2006, Blood.

Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro

C. Rooney, Colton A. Smith, C. Smith, 1996, Journal of virology.

An inducible caspase 9 safety switch for T-cell therapy.

H. Heslop, C. Rooney, K. Straathof, 2005, Blood.

Adenovirus as an emerging pathogen in immunocompromised patients

C. Rooney, A. Leen, 2005, British journal of haematology.

Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program

J. Wagner, C. Rooney, R. Lindblad, 2015, Transfusion.

NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors

C. Rooney, S. Gottschalk, L. Metelitsa, 2019, Cancer Immunology Research.

Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells

C. Rooney, Y. Okuno, Y. Nakazawa, 2017, Molecular therapy. Methods & clinical development.

Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.

C. Rooney, S. Gottschalk, M. Brenner, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.

Hao Liu, H. Heslop, C. Rooney, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.

R. Krance, C. Martinez, Hao Liu, 2015, Blood.

Systemic inflammatory response syndrome after administration of unmodified T lymphocytes.

R. Krance, H. Heslop, C. Rooney, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

H. Heslop, C. Rooney, M. Brenner, 2006, Blood.

Current challenges for CAR T‐cell therapy of acute myeloid leukemia

C. Rooney, T. Sauer, 2019, Transfusion.

Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells

C. Rooney, S. Gottschalk, M. Mukherjee, 2018, Front. Med..

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.

H. Heslop, C. Rooney, K. Straathof, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Autologous Designer Antigen-presenting Cells by Gene Modification of T Lymphocyte Blasts With IL-7 and IL-12

T. Okamura, C. Rooney, C. Bollard, 2007, Journal of immunotherapy.

Ex vivo gene transfer for improved adoptive immunotherapy of cancer.

H. Heslop, C. Rooney, Minhtran C. Ngo, 2011, Human molecular genetics.

Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.

C. Rooney, Y. Nakazawa, E. Yvon, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function.

C. Rooney, B. Eing, C. Rossig, 2007, Cancer research.

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

H. Heslop, C. Rooney, W. Wels, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

The clinical use of LMP2-specific cytotoxic T lymphocytes for the treatment of relapsed EBV +ve Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL)

H. Heslop, C. Rooney, C. Bollard, 2006 .

Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target κ-Light Immunoglobulin Chain

H. Heslop, C. Rooney, C. Ramos, 2013 .

T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor–Expressing T Cells

R. Krance, Hao Liu, H. Heslop, 2019, Clinical Cancer Research.

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.

Y. Zu, C. Cruz, Hao Liu, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adoptive Immunotherapy for Hodgkin’s Lymphoma

C. Rooney, C. Bollard, A. Kennedy-Nasser, 2006, International journal of hematology.

Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system.

S. Chen, C. Rooney, I. Schmidt-Wolf, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.

C. Rooney, D. Kirn, C. Breitbach, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.

R. Krance, K. Leung, C. Martinez, 2014, Blood.

Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation.

H. Heslop, C. Rooney, M. Brenner, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Adoptive cellular immunotherapy for EBV lymphoproliferative disease.

H. Heslop, C. Rooney, 1997, Immunological reviews.

A Costimulatory CAR Improves TCR-based Cancer Immunotherapy

C. Rooney, S. Gottschalk, N. Nouraee, 2022, Cancer immunology research.

An Inducible Caspase 9 Safety Switch Can Halt Cell Therapy-Induced Autoimmune Disease1

T. Schumacher, C. Rooney, J. Haanen, 2008, The Journal of Immunology.

Toward Immunotherapy With Redirected T Cells in a Large Animal Model: Ex Vivo Activation, Expansion, and Genetic Modification of Canine T Cells

C. Rooney, S. Gottschalk, H. Wilson-Robles, 2014, Journal of immunotherapy.

Peripheral Blood–Derived Virus-Specific Memory Stem T Cells Mature to Functional Effector Memory Subsets with Self-Renewal Potency

C. Rooney, H. Volk, P. Reinke, 2015, The Journal of Immunology.

Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials

C. Rooney, A. Leen, 2012, Molecular therapy. Nucleic acids.

Activation of Wnt Signaling Arrests Effector Differentiation in Human Peripheral and Cord Blood-Derived T Lymphocytes

J. Rodgers, P. Hanley, C. Rooney, 2011, The Journal of Immunology.

Target Antigen Expression on a Professional Antigen-Presenting Cell Induces Superior Proliferative Antitumor T-Cell Responses via Chimeric T-Cell Receptors

C. Rooney, H. Jürgens, M. Brenner, 2006, Journal of immunotherapy.

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.

P. Hanley, G. Demmler-Harrison, Hao Liu, 2010, Blood.

reconstitution after haploidentical stem cell transplant Adoptive immunotherapy with allodepleted donor T-cells improves immune

H. Heslop, C. Rooney, M. Cobbold, 2013 .

Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.

R. Krance, H. Heslop, C. Rooney, 2006, Blood.

TREATMENT OF SOLID ORGAN TRANSPLANT RECIPIENTS WITH AUTOLOGOUS EPSTEIN BARR VIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES (CTL). Running title: T cell therapy for PTLD in Solid organ transplant recipients

H. Heslop, C. Rooney, P. Reinke, 2006 .

Options for T‐cell based therapies

H. Heslop, C. Rooney, C. Bollard, 2004, Vox sanguinis.

Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.

R. Kruse, Daofeng Liu, Hao Liu, 2017, Cancer discovery.

Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model

C. Rooney, A. Foster, Matthew H. Wilson, 2015, PloS one.

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

Martin Pule, Adrian P Gee, Helen E Heslop, 2011, Blood.

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

Hao Liu, H. Heslop, C. Rooney, 2011, The Journal of clinical investigation.

CD70-specific CAR T-cells have potent activity against Acute Myeloid Leukemia (AML) without HSC toxicity.

C. Rooney, C. Müller-Tidow, S. Gottschalk, 2021, Blood.

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

Hao Liu, H. Heslop, C. Rooney, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.

J. Serody, A. Ivanova, H. Heslop, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity.

H. Heslop, C. Rooney, Colton A. Smith, 1997, Molecular medicine today.

Distinctions between endemic and sporadic forms of epstein‐barr virus‐positive burkitt's lymphoma

M. Epstein, C. Rooney, D. Moss, 1985, International journal of cancer.

Epstein‐Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma

C. Rooney, G. Lenoir, M. Rowe, 1986, International journal of cancer.

Differential activation of cytotoxic responses by Burkitt's lymphoma (BL)-cell lines: relationship to the BL-cell surface phenotype.

C. Rooney, G. Lenoir, A. Rickinson, 1986, Cellular immunology.

Paired epstein‐barr virus‐carrying lymphoma and lymphoblastoid cell lines Burkitt's lymphoma patients: Comparative sensitivity to non‐specific and to allo‐specific cytotoxic responses in vitro

M. Epstein, C. Rooney, D. Moss, 1984, International journal of cancer.

Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus

C. Rooney, G. Miller, S. Speck, 1989, Journal of virology.

Slc11a1 (formerly Nramp1) polymorphisms and susceptibility to post‐transplant lymphoproliferative disease following pediatric liver transplantation

C. Rooney, N. Barshes, J. Goss, 2006, Transplant infectious disease : an official journal of the Transplantation Society.

An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies

H. Heslop, C. Rooney, C. Ramos, 2010, Stem cells.

Quantitative EBV Viral Loads and Immunosuppression Alterations can Decrease PTLD Incidence in Pediatric Liver Transplant Recipients

H. Heslop, C. Rooney, N. Barshes, 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Autoimmune disease induced by dendritic cell immunization against leukemia.

C. Rooney, N. Suzuki, M. Brenner, 1999, Leukemia research.

The Use of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus Induced Lymphoma in Transplant Recipients

H. Heslop, C. Rooney, B. Savoldo, 2000, Leukemia & lymphoma.

Epstein–Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance

C. Rooney, M. Rowe, A. Rickinson, 1985, Nature.

Differential expression of viral and human interleukin-10 (IL-10) by primary B cell tumors and B cell lines.

F. Behm, J. Stewart, C. Rooney, 1994, Virology.

Changes in Chemokine Receptor Expression of Regulatory T Cells After Ex Vivo Culture

C. Rooney, B. Savoldo, G. Dotti, 2012, Journal of immunotherapy.

Post-transplant lymphoproliferative disorders.

H. Heslop, C. Rooney, S. Gottschalk, 2005, Annual review of medicine.

Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy.

C. Rooney, M. Brenner, B. Savoldo, 2001, Experimental hematology.

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.

H. Heslop, C. Rooney, M. Mims, 2008, Blood.

Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer

M. Ellis, C. Osborne, H. Heslop, 2022, Therapeutic advances in medical oncology.

Epstein Barr Virus-Specific T-cells grafted with Minor Histocompatibility Antigen HA-1 Specificity by Retroviral T-cell Receptor Transfer

C. Rooney, C. Bollard, K. Straathof, 2006 .

Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506).

H. Heslop, C. Rooney, F. Pane, 2008, Blood.

Autologous HER2 CMV bispecific CAR T cells for progressive glioblastoma: Results from a phase I clinical trial.

R. Grossman, S. Powell, Y. Kew, 2015 .

Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells

C. Rooney, R. Welch, Sunandan Saha, 2015, Nucleic acids research.

Cytotoxic T lymphocyte-mediated immunotherapy

C. Rooney, Colton A. Smith, G. Kitchingman, 1995 .

Adoptive cellular immunotherapy for viral diseases

H. Heslop, C. Rooney, Y. Fujita, 2008, Bone Marrow Transplantation.

The interleukin-10 homolog encoded by Epstein-Barr virus enhances the reactivation of virus-specific cytotoxic T cell and HLA-unrestricted killer cell responses.

J. Stewart, C. Rooney, 1992, Virology.

T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.

C. Rooney, A. Foster, D. Spencer, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Structure and function of the Epstein-Barr virus BZLF1 protein

C. Rooney, G. Packham, P. Farrell, 1990, Journal of virology.

Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.

H. Heslop, C. Rooney, Sandhya Sharma, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines.

C. Rooney, M. Rowe, A. Rickinson, 1986, Journal of the National Cancer Institute.

Adenoviral infections in hematopoietic stem cell transplantation.

C. Rooney, C. Bollard, A. Leen, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.

Zhensheng Liu, R. Krance, H. Heslop, 2000, Blood.

Immunotherapy for Post‐Transplant Lymphoproliferative Disease

H. Heslop, C. Rooney, K. Straathof, 2002, British journal of haematology.

Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation.

H. Heslop, C. Rooney, H. Wagner, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

for the adoptive Immunotherapy of EBV-associated malignancies Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen

A. Davis, H. Heslop, C. Rooney, 2013 .

malignancies antigen for the adoptive immunotherapy of EBV-associated Generating CTLs against the subdominant Epstein-Barr virus LMP1

A. Davis, H. Heslop, C. Rooney, 2013 .

Abstract LB-147: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas

H. Heslop, C. Rooney, K. Sanber, 2019, Clinical Research (Excluding Clinical Trials).

Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma.

Hao Liu, H. Heslop, C. Rooney, 2017 .

Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.

R. Grossman, S. Powell, H. Heslop, 2015, Journal of Immunotherapy for Cancer.

Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes.

C. Rooney, L. Rollins, G. Sønderstrup, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adoptive T-Cell Therapy for EBV-Associated Post-Transplant Lymphoproliferative Disease

H. Heslop, C. Rooney, C. Bollard, 2003, Acta Haematologica.

Hitchhiker's guide to the T cell

C. Rooney, 2005, Nature Medicine.

Cellular Immunity to Epstein‐Barr Virus in Liver Transplant Recipients Treated with Rituximab for Post‐Transplant Lymphoproliferative Disease

H. Heslop, C. Rooney, M. Finegold, 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.

Zhensheng Liu, H. Heslop, C. Rooney, 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Gene marking after bone marrow transplantation.

R. Krance, H. Heslop, C. Rooney, 1994, European journal of cancer.

Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo

C. Rooney, R. Welch, Sunandan Saha, 2018, Nature Communications.

Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1.

J. Stewart, C. Sample, C. Rooney, 1995, Virology.

Selective lack of antibody to a component of EB nuclear antigen in patients with chronic active Epstein-Barr virus infection.

R. Schooley, W. Andiman, L. Heston, 1987, The Journal of infectious diseases.

Correction of Duncan's syndrome by allogeneic bone marrow transplantation

R. Krance, H. Heslop, C. Rooney, 1993, The Lancet.

Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications.

C. Rooney, P. Piedra, M. Brenner, 2004, Blood.

Fiber-modified Adenoviruses Generate Sub-group Cross-reactive, Adenovirus-specific Cytotoxic T Lymphocytes for Therapeutic Applications Short title: Adenovirus-specific, cytotoxic T lymphocytes for Immunotherapy purposes

C. Rooney, P. Piedra, M. Brenner, 2003 .

Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts. St. Jude Children's Research Hospital, Memphis, Tennesse

R. Krance, H. Heslop, C. Rooney, 1994 .

Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.

P. Hanley, G. Demmler-Harrison, Hao Liu, 2011, Cytotherapy.

T‐Cell Immunotherapy for Adenoviral Infections of Stem‐Cell Transplant Recipients

H. Heslop, C. Rooney, C. Bollard, 2005, Annals of the New York Academy of Sciences.

Immunotherapy to reconstitute immunity to DNA viruses.

H. Heslop, C. Rooney, B. Gahn, 2002, Seminars in hematology.

Expression of the BZLF1 latency-disrupting gene differs in standard and defective Epstein-Barr viruses

C. Rooney, J. Countryman, G. Miller, 1989, Journal of virology.

Natural killer cell activity following T‐cell depleted allogeneic bone marrow transplantation

C. Rooney, A. Hoffbrand, M. Brenner, 1986, British journal of haematology.

The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle

C. Rooney, P. Farrell, T. Ragot, 1989, Journal of virology.

Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes.

R. Krance, H. Heslop, C. Rooney, 2004, Transplantation.

Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease.

H. Heslop, C. Rooney, B. Savoldo, 2004, Best practice & research. Clinical haematology.

Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients

H. Heslop, C. Rooney, M. Brenner, 2022, Haematologica.

Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.

J. Wagner, J. Tolar, C. Rooney, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

New insights into EBV-associated post-transplant lymphoproliferative disease

C. Rooney, 2003, The Lancet.

Inducible apoptosis as a safety switch for adoptive cell therapy.

Adrian P Gee, Helen E Heslop, Cliona M Rooney, 2011, The New England journal of medicine.

infusion of T cells expressing the inducible caspase 9 safety transgene Long-term outcome after haploidentical stem cell transplant and

R. Krance, C. Martinez, Hao Liu, 2014 .

An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies.

H. Heslop, C. Rooney, C. Ramos, 2009 .

Identification of protective T-cell antigens for smallpox vaccines

C. Rooney, Minhtran C. Ngo, A. Leen, 2020, Cytotherapy.

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.

Adrian P Gee, Helen E Heslop, Cliona M Rooney, 2005, Blood.

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

P. Hanley, C. Cruz, Hao Liu, 2009, Blood.

Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT)

S. Pai, H. Heslop, C. Rooney, 2010 .

Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.

H. Heslop, C. Rooney, W. Xie, 2003, Cytotherapy.

CTLs lymphoproliferative disease unresponsive to therapy with virus-specific An Epstein-Barr virus deletion mutant associated with fatal

H. Heslop, C. Rooney, Colton A. Smith, 2013 .

disease Prompt versus preemptive intervention for EBV lymphoproliferative

H. Heslop, C. Rooney, A. Gee, 2013 .

EBV Lymphoproliferative Disease After Transplantation

H. Heslop, C. Rooney, S. Gottschalk, 2008 .

Review Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells

C. Rooney, N. Suzuki, M. Brenner, 2005 .

Immunotherapy for Epstein-Barr virus-associated cancers.

H. Heslop, C. Rooney, C. Smith, 1998, Journal of the National Cancer Institute. Monographs.

Endemic and sporadic cases of Epstein-Barr virus-positive Burkitt's lymphoma: immunological characterization of derived cell lines.

M. Epstein, C. Rooney, G. Lenoir, 1985, Haematology and blood transfusion.

Posttransplant lymphoproliferative disease following liver transplantation

H. Heslop, C. Rooney, K. Kamdar, 2011, Current opinion in organ transplantation.

Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high‐risk for EBV infection

H. Heslop, C. Rooney, N. Barshes, 2006, Clinical transplantation.

Use of cytokine polymorphisms and Epstein–Barr virus viral load to predict development of post‐transplant lymphoproliferative disorder in paediatric liver transplant recipients

H. Heslop, C. Rooney, N. Barshes, 2006, Clinical transplantation.

Gene Transfer into Hemopoietic Progenitors: Implications for Bone Marrow Transplantation

H. Heslop, C. Rooney, M. Brenner, 1996 .

Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy

P. Hanley, C. Cruz, S. Lam, 2013, Clinical and experimental immunology.

Patients with Psoriasis Have High Serum Reactivity with EBNA-2B

C. Rooney, B. Baker, 1991 .

Anti-interleukin-10 antibodies in patients with chronic active Epstein-Barr virus infection.

C. Rooney, F. Diaz-Mitoma, J. Tanner, 1997, The Journal of infectious diseases.

Epstein-Barr infection after bone marrow transplantation.

R. Krance, H. Heslop, C. Rooney, 1994, Blood.

Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma.

M. Epstein, C. Rooney, D. Moss, 1985, IARC scientific publications.

Multi-Virus-Specific T-Cell Therapy For Patients After Hematopoietic Stem Cell and Cord Blood Transplantation

R. Krance, K. Leung, C. Martinez, 2013 .

CD30‐CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR THERAPY OF HODGKIN LYMPHOMA (HL)

H. Heslop, C. Rooney, C. Ramos, 2018, Hematological Oncology.

adenovirus-specific cytotoxic T lymphocytes for therapeutic applications Fiber-modified adenoviruses generate sub-group cross-reactive,

C. Rooney, P. Piedra, M. Brenner, 2013 .

Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus.

C. Rooney, G. Miller, S. Speck, 1989, Journal of virology.

244: Treatment of Epstein Barr Virus Positive Nasopharyngeal Carcinoma with Adoptively Transferred Cytotoxic T Lymphocytes

H. Heslop, C. Rooney, C. Bollard, 2008 .

The Use of Autologous LMP2-Specific Cytotoxic T Lymphocytes (CTL) for the Treatment of Relapsed EBV-Positive Hodgkin Disease and Non-Hodgkin Lymphoma.

H. Heslop, C. Rooney, C. Bollard, 2005 .

Production assistance for cellular therapies

C. Rooney, T. Whiteside, A. Donnenberg, 2004, Transfusion.

5: Long-Term Follow-Up of Administration of Donor-Derived EBV-Specific CTLs to Prevent and Treat EBV Lymphoma After Hemopoietic Stem Cell Transplant

H. Heslop, C. Rooney, C. Bollard, 2008 .

Harnessing the immune system to potentiate oncolytics.

C. Rooney, S. Gottschalk, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Immune therapy for EBV infections after hemopoietic stem-cell transplant.

H. Heslop, C. Rooney, C. Bollard, 2002, Cytotherapy.

Immunotherapy for Hodgkin's disease.

H. Heslop, C. Rooney, C. Bollard, 2002, Annals of hematology.

Gene Transfer of IL-7R alpha (IL-7Rα) on Antigen-Specific Cytotoxic T Cells (CTLs) Restores Their Ability To Respond to IL-7 Cytokine.

H. Heslop, C. Rooney, M. Brenner, 2007 .

Adoptive immunotherapy for herpesviruses.

C. Rooney, C. Bollard, A. Leen, 2007 .

Three-Module Signaling Endo-Domain Artifical T-Cell Receptor Which Transmits CD28, OX40 and CD3-ζ Signals Enhances IL-2 Release and Proliferative Response in Transduced Primary T-Cells.

H. Heslop, C. Rooney, K. Straathof, 2004 .

Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy.

C. Cruz, S. Lam, C. Rooney, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Abstract 3500: T cells redirected against HER2 for the adoptive immunotherapy for HER2-positive osteosarcoma

Hao Liu, H. Heslop, C. Rooney, 2012 .

Optimal Xenogeneic Adoptive Transfer of Human NK Cells: Fresh NK Cells and IL-15 Administration Are Superior to Frozen NK Cells and IL-2

J. Wagner, J. Tolar, C. Rooney, 2012 .

The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study.

D. Pierson, Zhensheng Liu, W. Keitel, 2003, The Journal of infectious diseases.

Prompt versus preemptive intervention for EBV lymphoproliferative disease.

R. Krance, H. Heslop, C. Rooney, 2004, Blood.

A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae

C. Rooney, C. Bollard, D. Kontoyiannis, 2018, Molecular therapy. Methods & clinical development.

Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT

Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney, 2014, Science Translational Medicine.

Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.

U. Gerdemann, R. Krance, K. Leung, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections

U. Gerdemann, H. Heslop, C. Rooney, 2012, Molecular Therapy.

Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation

H. Heslop, C. Rooney, C. Bollard, 2007, Bone Marrow Transplantation.

Childhood Leukemias: Adoptive cellular immunotherapy

H. Heslop, C. Rooney, 2006 .

Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells.

C. Rooney, W. Xie, P. Piedra, 2004, Blood.

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Hao Liu, H. Heslop, C. Rooney, 2008, Nature Medicine.

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

H. Heslop, C. Rooney, C. Ramos, 2021, Blood.

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

C. Cruz, S. Lam, R. Krance, 2013, Blood.

Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation

Ann M Leen, Cliona M Rooney, C. Rooney, 2010, Expert opinion on biological therapy.

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

S. Pai, H. Heslop, C. Rooney, 2013, Blood.

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial

R. Grossman, S. Powell, Y. Kew, 2017, JAMA oncology.

Clinical grade purification and expansion of natural killer cells.

C. Rooney, F. van Rhee, N. Lapteva, 2014, Critical reviews in oncogenesis.

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

C. Rooney, M. Brenner, A. Foster, 2010, Journal of immunotherapy.

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.

H. Heslop, C. Rooney, W. Fisher, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Reversal of tumor immune inhibition using a chimeric cytokine receptor.

H. Heslop, C. Rooney, Somala Mohammed, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

J. Massagué, H. Heslop, C. Rooney, 2002, Blood.

C. Creighton, Hao Liu, H. Heslop, 2014, Blood.

Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.

J. Melenhorst, H. Heslop, C. Rooney, 2010, Blood.

Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients

D. Campana, B. Barlogie, C. Rooney, 2015, Journal of immunotherapy.

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.

Elaine Coustan-Smith, Dario Campana, Tarun Garg, 2012, Cytotherapy.

Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling

Hao Liu, H. Heslop, C. Rooney, 2016 .

PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.

C. Rooney, Y. Nakazawa, L. Rollins, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.

Pradip Bajgain, Roopa Mucharla, Usanarat Anurathapan, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Regression of experimental medulloblastoma following transfer of HER2-specific T cells.

R. Gilbertson, H. Heslop, C. Rooney, 2007, Cancer research.

Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients

D. Campana, B. Barlogie, C. Rooney, 2012 .

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Hao Liu, H. Heslop, C. Rooney, 2010, Blood.

Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor

H. Heslop, C. Rooney, C. Bollard, 2008, Journal of immunotherapy.

Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.

Margaret A Goodell, Cliona M Rooney, C. Rooney, 2016, Cell reports.

Gene-marking and haemopoietic stem-cell transplantation.

H. Heslop, C. Rooney, M. Brenner, 1995, Blood reviews.

Enhancement of dendritic cells as vaccines for cancer.

C. Rooney, Meghan E. Turnis, 2010, Immunotherapy.

IRAK-M Removal Counteracts Dendritic Cell Vaccine Deficits in Migration and Longevity

C. Rooney, S. Gottschalk, Xiao-tong Song, 2010, The Journal of Immunology.

Vaccine Deficits in Migration and Longevity IRAK-M Removal Counteracts Dendritic Cell

C. Rooney, S. Gottschalk, Xiao-tong Song, 2010 .

Longevity Cell Vaccine Deficits in Migration and IRAK-M Removal Counteracts Dendritic

Foster, C. Rooney, S. Gottschalk, 2010 .

Role of TGF-β in Tumor Protection and Antitumor Immunity

C. Rooney, C. Bollard, 2008 .

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.

J. Orange, C. Rooney, J. Cabral, 2017, Cell reports.

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

D. Srivastava, R. Krance, H. Heslop, 1998, Blood.

Transfection and gene expression in normal and malignant primary B lymphocytes.

C. Rooney, H. Drexler, M. Buschle, 1990, Journal of immunological methods.

Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.

H. Heslop, C. Rooney, C. Smith, 1995, Journal of hematotherapy.

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.

P. Hanley, C. Cruz, R. Krance, 2009, Blood.

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

R. Krance, H. Heslop, C. Rooney, 1995, The Lancet.

Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients

D. Srivastava, R. Krance, H. Heslop, 1998 .

Improving T cell therapy for cancer.

C. Rooney, A. Foster, 2007, Expert opinion on biological therapy.

Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?

S. Shurtleff, K. Cornetta, S. Rosenberg, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Induction of Vigorous Helper and Cytotoxic T Cell as well as B Cell Responses by Dendritic Cells Expressing a Modified Antigen Targeting Receptor-Mediated Internalization Pathway1

C. Rooney, L. Rollins, Xue F. Huang, 2000, The Journal of Immunology.

Adoptive T-Cell Immunotherapy.

C. Rooney, S. Gottschalk, 2015, Current topics in microbiology and immunology.

Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency.

C. Rooney, J. Countryman, G. Miller, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Improving T Cell Therapy for Relapsed EBV-Negative Hodgkin's Lymphoma by Targeting Upregulated MAGE-A4

U. Gerdemann, C. Cruz, H. Heslop, 2011 .

Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4

U. Gerdemann, C. Cruz, H. Heslop, 2011, Clinical Cancer Research.

Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells

C. Rooney, P. Kinchington, Minhtran C. Ngo, 2017, Clinical Cancer Research.

T-cell therapy in the treatment of post-transplant lymphoproliferative disease

H. Heslop, C. Rooney, C. Bollard, 2012, Nature Reviews Clinical Oncology.

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

Chung-Che Chang, Adrian P Gee, Helen E Heslop, 2006, Nature Medicine.

Adoptive T Cell Transfer

C. Rooney, D. Shaffer, C. Cruz, 2013 .

Optimizing the production of suspension cells using the G-Rex “M” series

David Hsu, John M Centanni, Pradip Bajgain, 2014, Molecular therapy. Methods & clinical development.

Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.

J. Michálek, H. Heslop, C. Rooney, 2003, Blood.

Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma

C. Cruz, H. Heslop, C. Rooney, 2010, Leukemia & lymphoma.

T lymphocytes targeting native receptors

H. Heslop, C. Rooney, A. Leen, 2014, Immunological reviews.

Human Papillomavirus Type 16 E6/E7-specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-associated Malignancies

E. Sturgis, Matthew L. Anderson, U. Gerdemann, 2013, Journal of immunotherapy.

Preventative and Preemptive Strategies for EBV Infection and PTLD After HSCT

C. Rooney, C. Bollard, R. Rouce, 2021 .

Improving T cell therapy for cancer

C. Rooney, A. Foster, 2006, Annual review of immunology.

Induction of Antigen-Specific Regulatory T Cells following Overexpression of a Notch Ligand by Human B Lymphocytes

C. Rooney, E. Yvon, M. Brenner, 2003, Journal of Virology.

Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma

C. Rooney, A. Dispenzieri, S. Russell, 2020, Leukemia.

A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells

H. Heslop, C. Rooney, C. Bollard, 2004, Cancer Gene Therapy.

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

H. Heslop, C. Rooney, H. Abken, 2007, Blood.

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

H. Heslop, C. Rooney, C. Ramos, 2015, Blood.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

R. Advani, Y. Oki, J. Radford, 2021, Annals of Hematology.

Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities

R. Kruse, C. Rooney, T. Shum, 2018, Expert opinion on biological therapy.

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.

Hao Liu, H. Heslop, C. Rooney, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Receptor–Modified T Cells

Petra Reinke, Sandhya Sharma, Hans-Dieter Volk, 2017, The Journal of Immunology.

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

Hao Liu, H. Heslop, C. Rooney, 2016, The Journal of clinical investigation.

Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.

C. Rooney, K. Koike, Y. Nakazawa, 2014, Cytotherapy.

HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

P. Hanley, C. Cruz, C. Rooney, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma

R. Grossman, S. Powell, Y. Kew, 2012, Journal of immunotherapy.

Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease

H. Heslop, C. Rooney, C. Bollard, 2004, The Journal of experimental medicine.

A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells

C. Rooney, R. Rouce, D. Quach, 2019, Journal of translational medicine.

Cancer Therapy : Preclinical See commentary by Rezvani , p . 6955 Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A 4

U. Gerdemann, C. Cruz, H. Heslop, 2011 .

Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.

Hong Wang, Cliona M Rooney, Anastasios Raptis, 2017, Cytotherapy.

Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy

Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney, 2007, Journal of Virology.

Adoptive cellular immunotherapy for EBV lymphoproliferative diseases

H. Heslop, C. Rooney, 1997 .

Donor T cells to treat EBV-associated lymphoma.

H. Heslop, C. Rooney, M. Brenner, 1994, The New England journal of medicine.

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer

C. Rooney, G. Palapattu, M. Mims, 2013, Prostate Cancer and Prostatic Diseases.

Antigen-specific T cell therapies for cancer.

H. Heslop, C. Rooney, T. Manzo, 2015, Human molecular genetics.

Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation.

U. Gerdemann, H. Heslop, C. Rooney, 2013, Blood.

Modeling cytokine release syndrome

C. Rooney, T. Sauer, 2018, Nature Medicine.

Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.

U. Gerdemann, Hao Liu, H. Heslop, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

HLA type‐independent generation of antigen‐specific T cells for adoptive immunotherapy

C. Rooney, H. Volk, P. Reinke, 2005, European journal of immunology.

A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2- donors.

C. Rooney, M. Marangolo, A. Foster, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

In vivo fluorescent optical imaging of cytotoxic T lymphocyte migration using IRDye800CW near-infrared dye.

Shi Ke, Sunkuk Kwon, Eva Sevick-Muraca, 2008, Applied optics.

Extensive cross-reactivity of adenovirus-specific cytotoxic T cells.

C. Rooney, C. Smith, G. Kitchingman, 1998, Human gene therapy.

A PHASE I STUDY EVALUATING THE USE OF ALLODEPLETED T CELLS TRANSDUCED WITH INDUCIBLE CASPASE 9 SUICIDE GENE AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION (CASPALLO)

R. Krance, K. Leung, H. Heslop, 2009 .

nducible Caspase 9 Suicide Gene to Improve the afety of Allodepleted T Cells after Haploidentical tem Cell Transplantation

H. Heslop, C. Rooney, M. Brenner, 2007 .

Immunotherapy for Virus-Associated Malignancies

H. Heslop, C. Rooney, U. Sili, 2002 .

Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates.

C. Rooney, Brendan H. Lee, V. Cerullo, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Lymphoma EBV-Positive Nasopharyngeal Carcinoma and Specificity in CTL Lines from Patients with Characterization of Latent Membrane Protein 2

H. Heslop, C. Rooney, C. Bollard, 2011 .

Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma

H. Heslop, C. Rooney, C. Bollard, 2005, The Journal of Immunology.

Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma1

H. Heslop, C. Rooney, C. Bollard, 2005, The Journal of Immunology.

T‐cell receptor sequencing demonstrates persistence of virus‐specific T cells after antiviral immunotherapy

Christopher A. Lazarski, D. Douek, S. Darko, 2019, British journal of haematology.

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Cliona M. Rooney, Ann M. Leen, Juan F. Vera, 2011, Journal of visualized experiments : JoVE.

The Generation and Characterization of LMP2-Specific CTLs for Use as Adoptive Transfer From Patients With Relapsed EBV-Positive Hodgkin Disease

A. Davis, H. Heslop, C. Rooney, 2004, Journal of immunotherapy.

Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals1

Zhensheng Liu, H. Heslop, C. Rooney, 2002, The Journal of Immunology.

Accelerated Production of Antigen-specific T Cells for Preclinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex)

Helen E Heslop, Ann M Leen, Cliona M Rooney, 2010, Journal of immunotherapy.

Developments in clinical cell therapy.

S. Heimfeld, M. Sabatino, C. Rooney, 2010, Cytotherapy.

Modeling cytokine release syndrome

C. Rooney, T. Sauer, 2018, Nature Medicine.

Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease

Helen E. Heslop, Cliona M. Rooney, Juan F. Vera, 2013, Haematologica.

Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.

P. Hanley, J. Melenhorst, R. Krance, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo

Michael L. Wang, Jing Wang, J. Roth, 2021, Blood advances.

What influence has B-cell depletion on viral infections?

C. Rooney, B. Savoldo, A. Kaka, 2007, Leukemia & lymphoma.

Immunologically Active Autoantigens : The Role of Toll-Like Receptors in the Development of Chronic Inflammatory Disease

S. Tangye, C. Rooney, K. Nichols, 2009 .

Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.

S. Lam, C. Rooney, C. Bollard, 2015, The Journal of infectious diseases.

Gene and Cell Transfer for Specific Immunotherapy

H. Heslop, C. Rooney, M. Brenner, 1998, Vox sanguinis.

Cytotoxic T cells and immunotherapy

C. Rooney, G. Kitchingman, 1998, Pediatric Radiology.

Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.

G. Lucchini, J. Orange, A. Gennery, 2016, The Journal of allergy and clinical immunology.

Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.

H. Heslop, C. Rooney, C. Bollard, 2012, Cytotherapy.

Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors.

R. Krance, H. Heslop, C. Rooney, 1996, Bone marrow transplantation.

Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo

C. Rooney, R. Welch, Sunandan Saha, 2018, Nature Communications.

Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy

H. Heslop, C. Rooney, M. Brenner, 2023, Journal for ImmunoTherapy of Cancer.

Proceedings of the 7th Biannual International Symposium on Nasopharyngeal Carcinoma 2015

Sugiyanto, Asma Abdul Rahman, C. Lemmen, 2016, BMC Proceedings.

, reactivation after allogeneic stem cell transplantation Immunotherapeutic strategies to prevent and treat human herpesvirus

U. Gerdemann, C. Rooney, C. Ramos, 2012 .

Chimeric T Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas

Hao Liu, H. Heslop, C. Rooney, 2015 .

Can Treg elimination enhance NK cell therapy for AML?

C. Rooney, 2014, Blood.

Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies,

C. June, H. Heslop, C. Rooney, 2011 .

Evaluation of Long-term Transgene Expression in piggyBac-Modified Human T Lymphocytes

Cliona M. Rooney, C. Rooney, Y. Nakazawa, 2013, Journal of immunotherapy.

CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity

C. Rooney, S. Gottschalk, B. Omer, 2019, Blood.

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.

C. Rooney, C. Müller-Tidow, S. Gottschalk, 2021, Blood.

Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease.

R. Krance, H. Heslop, C. Rooney, 2000 .

Targeting CD19 with genetically modified EBV-specific human T lymphocytes.

C. Rooney, M. Brenner, H. Juergens, 2002, Annals of hematology.

Use of gene marking in bone marrow transplantation.

R. Krance, H. Heslop, C. Rooney, 1996, Cancer detection and prevention.

Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor-Associated Antigens

U. Gerdemann, Hao Liu, H. Heslop, 2016 .

Transfer of marker genes into hemopoietic progenitor cells.

R. Krance, H. Heslop, C. Rooney, 1996, Cytokines and molecular therapy.

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

H. Heslop, C. Rooney, C. Ramos, 2022, Blood.

Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes

C. Rooney, P. Farrell, M. Buschle, 1992, Journal of virology.

Cellular immunotherapy of EBV-associated lymphomas

H. Heslop, C. Rooney, Colton A. Smith, 1998 .

The United Kingdom public health response to an imported laboratory confirmed case of a novel coronavirus in September 2012.

R. Pebody, C. Rooney, A. Bermingham, 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy.

C. Rooney, L. Rollins, A. Gee, 2016, Methods in molecular biology.

Adenovirus immunity: X marks the spot.

C. Rooney, Masataka Suzuki, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease.

C. Rooney, C. Bollard, U. Popat, 2000, Human gene therapy.

Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies

C. Rooney, P. Lulla, D. Quach, 2022, Blood.

A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells

C. Rooney, R. Rouce, D. Quach, 2019, Journal of Translational Medicine.

Carcinoma and Lymphoma Patients with EBV-Positive Nasopharyngeal Protein 2 Specificity in CTL Lines from Characterization of Latent Membrane Rooney and

H. Heslop, C. Rooney, C. Bollard, 2005 .